MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Leukemia, Hematologic, Blood
Bio-Path Holdings, Inc (NASDAQ: BPTH)*
Organization & Developments: Bio-Path Holdings
Parents
Bio-Path Holdings, Inc (NASDAQ: BPTH)*
Children
*The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML).
2024: Initiated a new program to develop BP1001-A for obesity and metabolic diseases, marking its first non-cancer use of the DNAbilize platform, with preclinical studies starting in 4Q 2024
Jumps
Finance & Acquisitions: Bio-Path Holdings
Key People: Bio-Path Holdings